HER-2 POSITIVE BREAST CANCER
Clinical trials for HER-2 POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER-2 POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HER-2 POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to boost breast cancer treatment before surgery
Disease control Recruiting nowThis study tests whether adding hormone therapy to standard chemotherapy and HER2-targeted therapy improves tumor response before surgery in people with HER2-positive breast cancer. About 30 adults with stage II to III disease will participate. The goal is to see if this combinat…
Matched conditions: HER-2 POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Legacy Health System • Aim: Disease control
Last updated Jun 18, 2026 11:51 UTC
-
New hope for advanced breast cancer patients who stopped responding to earlier therapies
Disease control Recruiting nowThis study tests a new drug called A166 in people with HER2-positive breast cancer that has spread and no longer responds to certain previous treatments. About 40 adults aged 18 to 75 will receive A166 to see if it shrinks tumors or slows the disease. The goal is to find a better…
Matched conditions: HER-2 POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
Biosimilar for breast cancer under Real-World scrutiny
Knowledge-focused Recruiting nowThis observational study is tracking 1,000 people with HER2-positive breast cancer who are receiving a pertuzumab biosimilar as part of their routine care. Researchers are looking at how the drug is used, how well it works, and any side effects in both neoadjuvant (before surgery…
Matched conditions: HER-2 POSITIVE BREAST CANCER
Sponsor: Société Algérienne de Formation et Recherche en Oncologie • Aim: Knowledge-focused
Last updated Jun 23, 2026 12:08 UTC